English (UK)
中文版Mito Biopharma 
Mito Biopharma is a leading company in designing safe chemical mitochondrial uncouplers for
therapeutic development. We have developed a transformative and proven platform technology supporting lead development. Proof-of-concept studies demonstrated broad applications of the platform and superiority of mechanism of action. Therapeutic leads are protected by strong IP protection (worldwide composition-of-matter patent protection). The technology impacts high-value markets including NASH/T2D, Covid-19, and cancer.
We have IND- leads for NASH/T2D, Covid-19, and liver metastatic cancer. Our current focus is on a NASH lead. The company is seeking resources to support the NASH lead for IND and Phase I development, as well as pipeline development.
Dr. "Victor" Shengkan Jin
Founder and CEOMSQ Ventures
Mr. Estigarribia Marc
MDMyriad Genetics
Myriad Genetics is a technology-enabled molecular diagnostics company, with worldwide presence. Our genetic tests play in Oncology, Women's Health (e.g., prenatal), and Mental Health areas.
Jackie Z
Business Development LeadNANELEC 
Mr. Theo Tsenis
Researcher- Funding- ExportsNanoTech Pharma Inc
Ms. Ruby Sun
Vice President of Business DevelopmentNeoProgen
Mr. Bill Niland
CEO
NeuroZone 
Neuro-Zone, since 13 years, supports drug discovery, drug repurposing and research projects in the fields of inflammation and age-related pathologies.
In particular, we have developed pathology-specific platforms to generate rapid and informative data on efficacy, toxicity, metabolism and mechanism of action, supported by proprietary technologies such as MicroTISSUE (dissecting microenvironment-cell interaction in complex inflammatory scenarios) or MITOS (a comprehensive analytical platform for quantitative analysis of mitochondrial function ).
Our approach enables effective selection and ranking of the most promising candidates per indication.
Moreover, we profile candidates at different level of complexity starting from:
a) pharmacology profiling (GPCR; Ion Channel receptors)
b) identification of biochemical pathways responsible for therapeutic efficacy (transcriptomics)
c) disease modified barrier permeability (BBB and endothelial)
Fabio Bianco
PresidentNew.Fa.Dem. Srl
New.Fa.Dem, a manufacturing company based in Italy and is authorized by Italian Agency of Drugs.
Conducts activities like R&D, Manufacturing, Distribution of ethical drugs, medical devices and cosmetics with own brand or private labeling.
Manufacturing of Creams, Gels, liquid, powder and suppositories.
Three important certifications:
• ISO 9001: 2015 for compliance with international quality management standards;
• ISO 13485: 2016 for congruence with the legislation relating to the quality of medical devices;
• GMP COMPLIANCE for the possession of authorizations and licenses for the production of pharmaceutical products.
Possibility of manufacturing medical devices and cosmetics of the same form in the facility in the near future.
Successfully present in Europe, Middle East and North Africa.
ISO Certifications for compliance of international standards of Quality Management and rules on the quality of Medical Devices.
Responsive Web Design powered by 